ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Sandoz Group Ag

Sandoz Group Ag (0SAN)

0.00
0.00
( 0.00% )

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
-
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
8,821
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
Precio Anterior
0.00
Precio de Apertura
-
Última hora de negociación
05:53:36
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
0.00
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
0.00
Beneficio por acción (BPA)
-
turnover
9.65B
Beneficio neto
77M

Acerca de Sandoz Group Ag

Sector
Med, Dental, Hosp Eq-whsl
Industria
Med, Dental, Hosp Eq-whsl
Sitio web
Sede
Rotkreuz, Che
Fundado
-
Sandoz Group Ag is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker 0SAN. The last closing price for Sandoz was CHF0. Over the last year, Sandoz shares have traded in a share price range of CHF 0.00 to CHF 0.00.

Sandoz currently has 0 shares in issue.

0SAN Últimas noticias

Francisco Ballester to retire; Peter Stenico appointed President Region International

Francisco Ballester to retire; Peter Stenico appointed President Region International Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International...

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference MEDIA RELEASE Strong first year as standalone company; global leader Sandoz...

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz takes further steps...

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal...

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz reports third-quarter and nine-month 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in...

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™...

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz reports second-quarter sales and half-year 2024 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of...

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches...

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar...

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe   Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

0SAN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Sandoz?
El precio actual de las acciones de Sandoz es CHF 0.00
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Sandoz?
Sandoz ha negociado en un rango de CHF 0.00 a CHF 0.00 durante el último año
¿Cuál es la moneda de reporte de Sandoz?
Sandoz presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Sandoz?
El último ingresos anual de Sandoz es USD 9.65B
¿Cuál es el último beneficio anual de Sandoz?
El último beneficio anual de Sandoz es USD 77M
¿Cuál es la dirección registrada de Sandoz?
La dirección registrada de Sandoz es SUURSTOFFI 14, ROTKREUZ, ROTKREUZ, 6343
¿Cuál es la dirección del sitio web de Sandoz?
La dirección del sitio web de Sandoz es www.sandoz.com
¿En qué sector industrial opera Sandoz?
Sandoz opera en el sector MED, DENTAL, HOSP EQ-WHSL

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ORCPOracle Power Plc
0.0265p
(69.87%)
1.28B
BODBotswana Diamonds Plc
0.185p
(32.14%)
40.45M
NOGNostrum Oil & Gas Plc
3.50p
(25.00%)
4.22k
FXPOFerrexpo Plc
86.20p
(17.12%)
3.71M
BBGIBbgi Global Infrastructure S.a.
142.00p
(16.58%)
25.66M
RAIRa International Group Plc
0.80p
(-87.69%)
23.14M
ARKArkle Resources Plc
0.20p
(-20.00%)
507.13k
W7LWarpaint London Plc
442.00p
(-16.92%)
1.74M
IMMImmupharma Plc
3.80p
(-15.74%)
8.41M
TPXTpximpact Holdings Plc
27.00p
(-15.63%)
194.18k
ORCPOracle Power Plc
0.0265p
(69.87%)
1.28B
NTVONativo Resources Plc
0.0017p
(0.00%)
613.02M
CPAICapai Plc
0.044p
(0.00%)
194.96M
SRCSigmaroc Plc
75.00p
(6.53%)
180.92M
SYMESupply@me Capital Plc
0.0029p
(5.45%)
175.52M
ALDRADJKD123 ALDRADJKD123 5 minutos hace
Unreal, the Democrats, Liberals and RINOS agenda,

https://youtu.be/ePCzrpAW0MU?si=MNdgmoSGJULDu4TG

https://youtu.be/v4HmMm30QY8?si=Z2yWw7CW-9Nlm7Gb

https://youtu.be/HoxM1fxsD90?si=_577nHZTjkB5kWNj

https://youtu.be/FOCGgi415Bo?si=GJjdm4536G
LTListener LTListener 5 minutos hace
Who knows but the volume is still very very small. If you are retail, I think you have to find an account in Canada, otherwise it is likely brokers or certain "sophisticated" investors scooping up scraps or settling out positions.

Hopefully we will get more detail in some update or P
RSPI
Psypheri Psypheri 5 minutos hace
Don't forget to burn your shib 

https://news.shib.io/2025/01/30/shiba-inu-burns-1-billion-shib-in-symbolic-milestone/
SHIBUSD
PennyMillions852 PennyMillions852 6 minutos hace
As long as they keep slapping the ask, I’m good with it! Hope it moves into the 6’s today!
IGPK
tw0122 tw0122 6 minutos hace
Nice news been running nicely $5.90 +'128%
LIPO
TAKURI TAKURI 6 minutos hace
R/S 1 for 300
PPS 0.10/300=0.0003333

BDPT
biosectinvestor biosectinvestor 6 minutos hace
Re "agnostic". While I agree the company has not said it has applied for agnostic approval, it has not applied in the U.S. yet at all, so not really saying anything new there.

However, the 21st Century Cures act makes both off label coverage and extensions of labels, once approved, a
NWBO
budfoxfun budfoxfun 7 minutos hace
Humus, a crucial component of soil, provides essential nutrients and microorganisms, creating highly fertile soils. However, the natural buildup of humus can take years. SGTM's manufacturing of HumiSoil takes only six months, making it a highly efficient and scalable solution for regenerating nutrie
SGTM
Debunkinator Debunkinator 7 minutos hace
Tomorrow 💎
$ASII Friday we’ll inform our shareholders of our preliminary revenue guidance for 2025, confirming that we’ll again surpass our revenue forecast as per our filed 8K. On our way to $750M in revenue in 5 yrs.https://tinyurl.com/ycx89kuz $Uplisting $NASDAQ
ASII NASDAQ UPLISTING
Huggy Bear Huggy Bear 8 minutos hace
Damn shame this blatant, highly promoted, mining scam doesn't have any gold.
NBRI
Alexulf Alexulf 8 minutos hace
2025 Brixton Metals Year? See the facts presented: https://investorshub.advfn.com/Brixton-Metals-Corp-BBBXF-31124
BBBXF
stink stack stink stack 8 minutos hace
What is the time frame that you predict for relist?
BOOM!
Thanks
FNMA
SC8 SC8 8 minutos hace
So why was at least one RDGL competitor that we know of able to start clinical trials in 2022 the moment the last Radiogel patent expired? MK had no such restriction and it took him most of a decade to start clinic trials. The guy is a gross incompetent.
RDGL
RobotDroid RobotDroid 9 minutos hace
Gonna be RED today, tomorrow, next week, next month. Instead of wondering when the next vote to increase the share count is, how about a vote to remove the worlds worst ceo and mute inept nonmanagement? That should be a priority.
NWBO
glenn1919 glenn1919 10 minutos hace
LAES.....BBAI.......SLXN......REBN......CPIX...........................https://stockcharts.com/h-sc/ui?s=IVVD&p=D&yr=0&mn=3&dy=0&id=p11960084343
BBAI CPIX IVVD
sunspotter sunspotter 10 minutos hace
"Is Leo a criminal genius? Is that why he has never been arrested or charged with a crime?"

Nah. It's just that anybody who still thinks IPIX and Leo are legit is criminally stupid.

P T Barnum said it best (apocryphally, at least).
IPIX
Alexulf Alexulf 10 minutos hace
2025 Brixton Metals Year? See the facts presented: https://investorshub.advfn.com/Brixton-Metals-Corp-BBBXF-31124
BBBXF
Budman33 Budman33 11 minutos hace
I cannot believe that we are a one time sale company. If we were why would there be offices in other countries. We are waiting for next order or two to come in
. Which I believe could be in next month or two. Will never sell at these prices.
VDRM
SC8 SC8 12 minutos hace
Neglecting to mention a competitor has a 2.5 year clinical trial head start over RDGL. Don't see how any safety claims can be made when indications to date are Radiogel is of little to no benefit for these 5 patients and even the treated tumors were underdosed with Radiogel.
RDGL
glenn1919 glenn1919 12 minutos hace
cldi.....dgly.......mrsn......muln.........................https://stockcharts.com/h-sc/ui?s=muln&p=D&yr=0&mn=3&dy=0&id=p11960084343
uranium-pinto-beans uranium-pinto-beans 12 minutos hace
Bank of England lowers Bank Rate by 0.25 percentage points to 4.5%
At its meeting ending on February 5, the Bank of England Monetary Policy Committee voted by a majority of 7-2 to reduce Bank Rate by 0.25 percentage points, to 4.5%. Two members preferred to reduce Bank Rate by 0.5 percentage
Jake731 Jake731 13 minutos hace
GOOD MORNING YALL










TPTW……!!!!!!!!!!!!!
TPTW
StayHumble StayHumble 13 minutos hace
Power2 the P1ayers💹24/7 interest here✅2 infinity! & beyond wow!!
GME
barnyarddog barnyarddog 14 minutos hace
Venu Sports, a sports streaming service that was supposed to launch from Fox, Warner Bros. Discovery, and Disney's ESPN (DIS).

The three companies first announced the joint venture last year, with an expected price point of $42.99 a month. The service was set to bring together their r
FUBO
PEACHMAN PEACHMAN 14 minutos hace
I just reread my IFUS post you referred to and listed it again for you and everyone to read below.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175762191.

Please show one statement or comment where I threatened you?????

It is easy to
IFUS